Regeneron (REGN) director receives 1,962 options and 155 RSUs on grant

Rhea-AI Filing Summary

Regeneron Pharmaceuticals director Craig B. Thompson reported new equity awards. On January 2, 2026, he acquired 155 time-based restricted stock units, each representing one share of Regeneron common stock, and 1,962 non-qualified stock options with a conversion (exercise) price of $772.76 per share.

After these grants, Thompson directly beneficially owned 775 shares of common stock and 1,962 stock options. A portion of the options will become exercisable on the date of Regeneron’s first annual shareholder meeting following the grant, in proportion to the part of a year that has elapsed since grant, with the remaining options becoming exercisable on the first anniversary of the grant date.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Thompson Craig B.

(Last) (First) (Middle)

777 OLD SAW MILL RIVER ROAD

(Street)

TARRYTOWN NY 10591

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
REGENERON PHARMACEUTICALS, INC. [ REGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A(1)		155	A	$0.0	775	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$772.76	01/02/2026		A		1,962		(2)	01/02/2036	Common Stock	1,962	$0.0	1,962	D

Explanation of Responses:

1. Reflects an acquisition of time-based vesting restricted stock units each representing a contingent right to receive one share of the Issuer's common stock.

2. On the date of the Issuer's first annual meeting of shareholders following the date of grant, a portion of these stock options equal to the portion of one year that has passed from the date of grant shall then become exercisable, and the remainder shall become exercisable on the first anniversary of the date of grant.

	/s/ Craig B. Thompson	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does Regeneron (REGN) director Craig B. Thompson report in this Form 4?

The filing reports that Craig B. Thompson, a director of Regeneron Pharmaceuticals, received new equity awards on January 2, 2026, consisting of restricted stock units and non-qualified stock options, and discloses his updated beneficial ownership.

How many Regeneron shares and options were granted to Craig B. Thompson?

Craig B. Thompson acquired 155 time-based restricted stock units, each tied to one share of Regeneron common stock, and 1,962 non-qualified stock options exercisable for Regeneron common stock.

What is the exercise price and expiration date of Craig B. Thompson’s Regeneron stock options?

The non-qualified stock options have a conversion (exercise) price of $772.76 per share and an expiration date of January 2, 2036, with 1,962 underlying shares of Regeneron common stock.

How and when do Craig B. Thompson’s Regeneron options vest?

According to the disclosure, on the date of Regeneron’s first annual meeting of shareholders following the grant, a portion of the stock options equal to the portion of one year that has passed since the grant will become exercisable, and the remainder becomes exercisable on the first anniversary of the grant date.

What are the terms of the restricted stock units reported by Craig B. Thompson at Regeneron?

The 155 units are described as time-based vesting restricted stock units, each representing a contingent right to receive one share of Regeneron’s common stock, subject to the applicable vesting conditions.

What is Craig B. Thompson’s ownership in Regeneron after these transactions?

Following the reported transactions, Craig B. Thompson beneficially owned 775 shares of Regeneron common stock directly, as well as 1,962 non-qualified stock options to purchase additional shares.